Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL)
Kathryn A Ellis, Cassandra Szoeke, Ashley I Bush, David Darby, Petra L Graham, Nicola T Lautenschlager, S Lance Macaulay, Ralph N Martins, Paul Maruff, Colin L Masters, Simon J McBride, Kerryn E Pike, Stephanie R Rainey-Smith, Alan Rembach, Joanne Robertson, Christopher C Rowe, Greg Savage, Victor L Villemagne, Michael Woodward, William Wilson Show all
INTERNATIONAL PSYCHOGERIATRICS | CAMBRIDGE UNIV PRESS | Published : 2014
BACKGROUND: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing is a prospective study of 1,112 individuals (211 with Alzheimer's disease (AD), 133 with mild cognitive impairment (MCI), and 768 healthy controls (HCs)). Here we report diagnostic and cognitive findings at the first (18-month) follow-up of the cohort. The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not. METHODS: Eighteen months after baseline, participants underwent comprehensive cognitive testing and diagnostic review, p..View full abstract
Funding for the study was provided in part by the study partners [Australian Commonwealth Scientific Industrial and Research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research Institute (MHRI), Alzheimer's Australia Vic (AA), National Ageing Research Institute (NARI), University of Melbourne, Austin Health, CogState Ltd., Hollywood Private Hospital, Sir Charles Gardner Hospital]. The study also received support from the National Health and Medical Research Council (NHMRC), the Dementia Collaborative Research Centres program (DCRC-EDP), and the McCusker Alzheimer's Research Foundation, Inc., as well as ongoing funding from the Science and Industry Endowment Fund (SIEF; www.SIEF.org.au). Pfizer International and GE Healthcare have contributed financial support to assist with analysis of blood samples and to further the AIBL research program. Ashley I. Bush is supported by a Federation Fellowship from the Australian Research Council. Cassandra Szoeke has received support from Alzheimer's Australia, the Ramiciotti Foundation, the Mason Foundation, and the NHMRC. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and screening of telephone calls from volunteers.